Serum testosterone levels and breast cancer recurrence

International Journal of Cancer

Volumn 113, Issue 3, 2005, Pages 499-502

  Berrino, Franco ^a   Pasanisi, Patrizia ^a   Bellati, Cristina ^a   Venturelli, Elisabetta ^a   Krogh, Vittorio ^a   Mastroianni, Antonio ^a   Berselli, Edoardo ^a   Muti, Paola ^b   Secreto, Giorgio ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Breast cancer; Recurrences; Testosterone

Indexed keywords

HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BODY MASS; BREAST CANCER; CONFIDENCE INTERVAL; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD ASSESSMENT; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RELAPSE; TESTOSTERONE BLOOD LEVEL;

BLOOD GLUCOSE; BODY MASS INDEX; BREAST NEOPLASMS; ESTRADIOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; POSTMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TESTOSTERONE;

EID: 11144285413     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20582     Document Type: Article

References (21)

1. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-16.
2. Vainio H, Bianchini F, eds. Weight control and physical activity. Lyon: IARC, 2002.
3. Kaaks R. Nutrition, hormones, and breast cancer: is insulin the missing link? Cancer Causes Control 1996;7:605-25.
4. Muti P, Quattrin T, Grant BJ, Krogh V, Micheli A, Schunemann HJ, Ram M, Freudenheim JL, Sieri S, Trevisan M, Berrino F. Fasting glucose is a risk factor for breast cancer: a prospective study. Cancer Epidemiol Biomarkers Prev 2002;11:1361-8.
5. Trichopoulos D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl Cancer Inst 1972;48:605-13.
6. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-88.
7. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
8. Early Breast Cancer Trialists' Collaborative Group. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet 1996;348:1189-96.
9. Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 2002;20:3302-16.
10. Camoriano JK, Loprinzi CL, Ingle JN, Therneau TM, Krook JE, Veeder MH. Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol 1990;8:1327-34.
11. Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002;20:1128-43.
12. Jernstrom H, Barrett-Connor E. Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo study. J Womens Health Gend Based Med 1999;8:1265-72.
13. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, Hartwick W, Hoffman B, Hood N. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol 2002;20:42-51.
14. Grattarola R, Secreto G, Recchione C. Androgens in breast cancer: III, breast cancer recurrences years after mastectomy and increased androgenic activity. Am J Obstet Gynecol 1975;121:169-72.
15. Secreto G, Zumoff B. Paradoxical effects associated with supranormal urinary testosterone excretion in premenopausal women with breast cancer: increased risk of postmastectomy recurrence and higher remission rate after ovariectomy. Cancer Res 1983;43:3408-11.
16. Secreto G, Zumoff B. Abnormal production of androgens in women with breast cancer. Anticancer Res 1994;14:2113-7.
17. Berrino F, Bellati C, Oldani S, Mastroianni A, Allegro G, Berselli E, Venturelli E, Cavalleri A, Cambie' M, Pala V, Pasanisi P, Secreto G. DIANA trials on diet and endogenous hormones. In: Riboli E, Lambert R, eds. Nutrition and lifestyle: opportunities for cancer prevention. Lyon: IARC Press, 2002. 439-44.
18. Berrino F, Bellati C, Secreto G, Camerini E, Pala V, Panico S, Allegro G, Kaaks R. Reducing bioavailable sex hormones through a comprehensive change in diet: the diet and androgens (DIANA) randomized trial. Cancer Epidemiol Biomarkers Prev 2001;10:25-33.
19. Poretsky L, Kalin MF. The gonadotropic function of insulin. Endocr Rev 1987;8:132-41.
20. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr 1987;45:277-82.
21. James VH, McNeill JM, Lai LC, Newton CJ, Ghilchik MW, Reed MJ. Aromatase activity in normal breast and breast tumor tissues: in vivo and in vitro studies. Steroids 1987;50:269-79.